Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

MIAMI, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced management will participate in the H.C. Wainwright 27^th Annual Global Investment Conference, taking place September 8-10, 2025 in New York City.

Read more at globenewswire.com